Tempest

Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 27, 2022
ASCO, Society, Annual general meeting, Nivolumab, GLOBE, Bevacizumab, Patient, American Society of Clinical Oncology, SAN, EDT, Johns Hopkins School of Medicine, Neoplasm, 2021 Essex County Council election, Therapy, Pharmaceutical industry, Tempest

The results of the Phase 1 monotherapy and Phase 1 combination therapy studies with TPST-1120, a potential first-in-class PPAR antagonist, received an invitation for an oral presentation.

Key Points: 
  • The results of the Phase 1 monotherapy and Phase 1 combination therapy studies with TPST-1120, a potential first-in-class PPAR antagonist, received an invitation for an oral presentation.
  • The trial results will be presented on the podium by Mark Yarchoan, a clinical investigator from Johns Hopkins School of Medicine.
  • In addition, the trials-in-progress abstract for TPST-1495, a potential first-in-class EP2/EP4 prostaglandin receptor dual antagonist, was accepted for a poster presentation.
  • We are thrilled that ASCO recognized our two novel clinical programs and accepted the abstracts for presentation, commented Stephen Brady, chief executive officer of Tempest.

Wind River Selected by BAE Systems for Team Tempest Advanced Combat Air Systems Development

Retrieved on: 
Tuesday, April 26, 2022
Data Management, Defense, Security, Technology, Other Technology, Software, Contracts, Wind River Systems, GNAT, VxWorks, ISO, Research, Program, BAE Systems Tempest, IEC, Technology, COTS, AI, Intelligence, Safety, BAE Systems, Multimedia, Industry, Certification, Risk, Wind, View, IEC 61508, Renewable energy, Tempest

Wind River , a global leader in delivering software for intelligent systems, today announced it has been selected by BAE Systems to support technology demonstration work as part of the Tempest future combat air system program.

Key Points: 
  • Wind River , a global leader in delivering software for intelligent systems, today announced it has been selected by BAE Systems to support technology demonstration work as part of the Tempest future combat air system program.
  • View the full release here: https://www.businesswire.com/news/home/20220426005579/en/
    We are honored be working with BAE Systems, said Avijit Sinha, chief product officer, Wind River.
  • Wind River Studio is a cloud-native platform for the development, deployment, operations, and servicing of mission-critical intelligent systems.
  • Wind River is a trademark or registered trademark of Wind River Systems, Inc., and its affiliates.

Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting

Retrieved on: 
Friday, April 8, 2022
Nonsteroidal anti-inflammatory drug, Therapy, Celecoxib, Form 10-K, DNA, Form, Forward-looking statement, Pharmacokinetics, Colorectal cancer, EP3, American Association for Cancer Research, Mouse, AACR, Survival, Tumor microenvironment, Program, PD, Neoplasm, Doxorubicin, Immunity, U.S. Securities and Exchange Commission, Bevacizumab, Â, Security (finance), CRC, Association, EP4, Safety, NSAID, Securities Exchange Act of 1934, PGE2, Goal, Securities Act of 1933, EP2, EP1, GLOBE, TREX1, Drug Quality and Security Act, NK, Nature, Stimulator of interferon genes, Patient, Vaccine, Pharmaceutical industry, Tempest

As part of our diversified pipeline of innovative therapeutics, we reported the first preclinical data from our TREX1 program demonstrating the significant anti-tumor activity of our selective inhibitors.

Key Points: 
  • As part of our diversified pipeline of innovative therapeutics, we reported the first preclinical data from our TREX1 program demonstrating the significant anti-tumor activity of our selective inhibitors.
  • These data support the enthusiasm for our ongoing Phase 1 monotherapy and combination dose escalation and optimization study.
  • In vivo data demonstrated that monotherapy TPST-1495 significantly reduced tumor growth in mice via both T cell-independent and T-cell dependent mechanisms.
  • These and other risks are described in greater detail in the Form 10-K filed by Tempest Therapeutics with the Securities and Exchange Commission on March 29, 2022.

The Canadian Vaping Association: New Brunswick vape retailers will seek leave to appeal

Retrieved on: 
Friday, April 1, 2022
Public health, Adoption, Smoking, CVA, Health, GLOBE, Norton, Smoker, Charter, Tempest, Tobacco

Beamsville, ON, April 01, 2022 (GLOBE NEWSWIRE) -- New Brunswick vape retailers and former smokers sought an injunction on the provinces licensing requirement which is the mechanism that enables a ban on flavours.

Key Points: 
  • Beamsville, ON, April 01, 2022 (GLOBE NEWSWIRE) -- New Brunswick vape retailers and former smokers sought an injunction on the provinces licensing requirement which is the mechanism that enables a ban on flavours.
  • The plaintiffs are requesting that the licensing requirement be suspended until the current constitutional challenge against the flavour ban is concluded.
  • The affidavits were critical to the inunction, but unfortunately, they were not considered in the decision.
  • Additionally, evidence of the destruction of Nova Scotias vape industry was submitted but not considered.

Tempest Reports Year End 2021 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 29, 2022
Therapy, Form 10-K, Form, Forward-looking statement, Society, ORR, AACR, Research, Immunotherapy, Hepatocellular carcinoma, American Association, Cancer, PIPE, U.S. Securities and Exchange Commission, Neoplasm, Bevacizumab, Roche, Association, American Association for Cancer Research, EP4, Patent, Securities Exchange Act of 1934, Annual general meeting, ASCO, EP2, Goal, Securities Act of 1933, GLOBE, TREX1, HCC, Nivolumab, Drug Quality and Security Act, Arm, SITC, Nature, Patient, Pembrolizumab, Security (finance), Pharmaceutical industry, Cryptocurrency, Tempest

This and the broader progress made in the pipeline positions Tempest for a potentially transformative 2022.

Key Points: 
  • This and the broader progress made in the pipeline positions Tempest for a potentially transformative 2022.
  • Tempest ended the year 2021 with $51.8 million in cash and cash equivalents, compared to $18.8 million at December 31, 2020.
  • The increase was primarily due to the merger and concurrent PIPE financing, which closed in June 2021.
  • Forward-looking statements are based on information available to Tempest Therapeutics as of the date hereof and are not guarantees of future performance.

Embry-Riddle Aeronautical University Receives $25M Gift from Cici and Hyatt Brown, Matching State of Florida Support

Retrieved on: 
Friday, March 25, 2022
Transfer, Trustee, CEO, Workforce, Wind tunnel, Center, Technology, Bellevue Avenue Historic District, PIV, Aviation, Commerce, ICI Homes, Education, History, State, Engineering, Invention, NASA Research Park, Particle image velocimetry, Food and Drug Administration, Senior, Laboratory, Quality of life, J. Hyatt Brown, Student, Floridian, Florida State Road 483, Patent, Data science, Economic development, Growth, Board, Bellevue, Injury, Board of directors, Secretary of State of Florida, Trauma, FDA, Weather, Infection, Malini Kishor Sanghvi College of Commerce & Economics, Technology transfer, List of research parks, Research, CTO, U.S. Department of Defense Strategy for Operating in Cyberspace, Renewable energy, Management, Warehouse, Çiçi, Tempest, Embry–Riddle Aeronautical University

DAYTONA BEACH, Fla., March 25, 2022 /PRNewswire-PRWeb/ -- Embry-Riddle Receives the Single-Largest Gift in its 96-Year History

Key Points: 
  • The remarkably generous $25 million pledge from Cici and Hyatt Brown represents the single largest gift in the history of Embry-Riddle Aeronautical University, which was established in 1926.
  • "Cici and I are excited to make this investment to help continue the growth and development of institutional excellence at Embry-Riddle Aeronautical University," Hyatt Brown said.
  • The new center, made possible by Cici and Hyatt Brown and the State of Florida, will take Embry-Riddle's already successful economic development efforts to a whole new level."
  • Cici and Hyatt Brown and the State of Florida have placed their faith in Embry-Riddle's ability to make good things happen.

Grand Theft Auto V and GTA Online Now Available for PlayStation 5 and Xbox Series X|S

Retrieved on: 
Tuesday, March 15, 2022
Entertainment, Consumer Electronics, Technology, Other Entertainment, Software, Electronic Games, Online, Midnight, TTWO, SEC, Time, Tempest 3D, HSW, GTA, L.A. Noire, Sony Interactive Entertainment, Acquisition, Minecraft: Story Mode, Annual report, Mode, Xbox One, Grand Theft Auto Online, ESRB, Tempest, PlayStation 5, Fidelity, Grand Theft Auto modding, Multimedia, Rock Star, Max Payne, Take-Two Interactive, Risk, Midnight Club, COVID-19, DualShock, PlayStation 4, Red Dead Redemption 2, HDR, 5, PlayStation, Microsoft, Los Santos, Publishing, Tablet, Microsoft Store, NASDAQ, PlayStation Store, Grand Theft Auto, Max Payne 3, Hope, Company, Xbox Series X and Series S, Federal Reserve, Private Division, Chameleon, Federal, Red Dead Redemption, Xbox, Rockstar Games, The Warriors, Video game, Video game console, Zynga, Rockstar Games, Take-Two Interactive Software, ROCKSTAR GAMES, TAKE-TWO INTERACTIVE SOFTWARE

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    Grand Theft Auto V and GTA Online are available together for $9.99 through the PlayStation Store and $19.99 through the Microsoft Store on Xbox through June 14, 2022, with physical releases coming in April.
  • The impact of Grand Theft Auto V continues to both humble and amaze us, said Sam Houser, founder of Rockstar Games.
  • Delivering the epic, action-packed experience of Grand Theft Auto V and the ever-evolving online universe of GTA Online to the latest generation of consoles for new and returning players, Grand Theft Auto V and GTA Online for PlayStation 5 and Xbox Series S|X debut with a host of new and improved features, making both games more player-friendly and easier to access than ever before.
  • Grand Theft Auto V and GTA Online are rated M for Mature by the ESRB.

Tempest Telecom Solutions Reintroduces and Redefines Itself as Tempest

Retrieved on: 
Monday, March 14, 2022
DAS, Time, COO, Government, Maintenance, Technology, VP, Marketing, Business, Original equipment manufacturer, Multimedia, Solution, Online shopping, Tempest

SANTA BARBARA, Calif., March 14, 2022 /PRNewswire/ -- Tempest Telecom Solutions, a national network solutions provider and Certified Women's Business Enterprise, unveils its rebrand to Tempest. As part of the rebrand, Tempest has launched its new website tempestns.com to introduce its expanded network solutions and deliver a best-in-class online experience for customers, reflecting the new brand identity.

Key Points: 
  • SANTA BARBARA, Calif., March 14, 2022 /PRNewswire/ --Tempest Telecom Solutions, a national network solutions provider and Certified Women's Business Enterprise, unveils its rebrand to Tempest.
  • As part of the rebrand, Tempest has launched its new website tempestns.com to introduce its expanded network solutions and deliver a best-in-class online experience for customers, reflecting the new brand identity.
  • Tempest is a national network solutions provider dedicated to delivering clever solutions to the complex challenges that slow down network operators.
  • The Tempest portfolio spans multi-vendor equipment supply, repair, logistics, remote technical services, network test and visibility, and critical power solutions.

Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference

Retrieved on: 
Thursday, March 10, 2022
Therapy, Neoplasm, GLOBE, Conference, Patient, Bevacizumab, SAN, Pharmaceutical industry, Tempest

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17, 2022 at 10:40 a.m.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17, 2022 at 10:40 a.m.
  • To access the live or archived recording of the company presentation, please visit the investor section of the Tempest website at https://ir.tempesttx.com .
  • Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors.
  • More information about Tempest can be found on the companys website at www.tempesttx.com .

Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, March 8, 2022
Online, AACR, Therapy, Bevacizumab, GLOBE, Patient, American Association, TREX1, Neoplasm, Association, SAN, Pharmaceutical industry, Tempest

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced two poster presentations at the 2022 American Association for Cancer Research (AACR) virtual annual meeting taking place April 8-13, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced two poster presentations at the 2022 American Association for Cancer Research (AACR) virtual annual meeting taking place April 8-13, 2022.
  • The presentations contain new preclinical data for two of Tempests small molecule programs, TPST-1495 (clinical-stage dual EP2/4 antagonist) and TREX1 (preclinical STING agonist).
  • Full abstracts are available for viewing in the AACR Online Itinerary Planner located here, https://www.abstractsonline.com/pp8/#!/10517 .
  • Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors.